Ang-(1-7)/ MAS1 receptor axis inhibits allergic airway inflammation via blockade of Src-mediated EGFR transactivation in a murine model of asthma


Autoři: Ahmed Z. El-Hashim aff001;  Maitham A. Khajah aff001;  Rhema S. Babyson aff001;  Waleed M. Renno aff002;  Charles I. Ezeamuzie aff003;  Ibrahim F. Benter aff004;  Saghir Akhtar aff005
Působiště autorů: Department of Pharmacology & Therapeutics, Faculty of Pharmacy, Kuwait University, Kuwait City, Kuwait aff001;  Department of Anatomy, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait aff002;  Department of Pharmacology and Toxicology, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait aff003;  Faculty of Medicine, Eastern Mediterranean University, Famagusta, North Cyprus aff004;  College of Medicine, Qatar University, Doha, Qatar aff005
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0224163

Souhrn

The angiotensin-(1–7) [Ang-(1–7)]/MAS1 receptor signaling axis is a key endogenous anti-inflammatory signaling pathway. However, the mechanisms by which its mediates the anti-inflammatory effects are not completely understood. Using an allergic murine model of asthma, we investigated whether Ang-1(1–7)/MAS1 receptor axis a): inhibits allergic inflammation via modulation of Src-dependent transactivation of the epidermal growth factor receptor (EGFR) and downstream signaling effectors such as ERK1/2, and b): directly inhibits neutrophil and/or eosinophil chemotaxis ex vivo. Ovalbumin (OVA)-induced allergic inflammation resulted in increased phosphorylation of Src kinase, EGFR, and ERK1/2. In addition, OVA challenge increased airway cellular influx, perivascular and peribronchial inflammation, fibrosis, goblet cell hyper/metaplasia and airway hyperresponsiveness (AHR). Treatment with Ang-(1–7) inhibited phosphorylation of Src kinase, EGFR, ERK1/2, the cellular and histopathological changes and AHR. Ang-(1–7) treatment also inhibited neutrophil and eosinophil chemotaxis ex vivo. These changes were reversed following pre-treatment with A779. These data show that the anti-inflammatory actions of Ang-(1–7)/ MAS1 receptor axis are mediated, at least in part, via inhibition of Src-dependent transactivation of EGFR and downstream signaling molecules such as ERK1/2. This study therefore shows that inhibition of the Src/EGRF/ERK1/2 dependent signaling pathway is one of the mechanisms by which the Ang-(1–7)/ MAS1 receptor axis mediates it anti-inflammatory effects in diseases such as asthma.

Klíčová slova:

Asthma – Cell enumeration techniques – Eosinophils – Chemotaxis – Inflammation – Mouse models – Neutrophils – Phosphorylation


Zdroje

1. Holgate ST. Mechanisms of asthma and implications for its prevention and treatment: a personal journey. Allergy Asthma Immunol Res. 2013;5(6):343–7. Epub 2013/11/02. doi: 10.4168/aair.2013.5.6.343 24179679; PubMed Central PMCID: PMC3810539.

2. Matucci A, Vultaggio A, Maggi E, Kasujee I. Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? Respiratory research. 2018;19(1):113. Epub 2018/06/09. doi: 10.1186/s12931-018-0813-0 [pii]. 29879991.

3. Carsin A, Mazenq J, Ilstad A, Dubus JC, Chanez P, Gras D. Bronchial epithelium in children: a key player in asthma. Eur Respir Rev. 2016;25(140):158–69. Epub 2016/06/02. doi: 10.1183/16000617.0101-2015 25/140/158 [pii]. 27246593.

4. El-Hashim AZ, Khajah MA, Renno WM, Babyson RS, Uddin M, Benter IF, et al. Src-dependent EGFR transactivation regulates lung inflammation via downstream signaling involving ERK1/2, PI3Kdelta/Akt and NFkappaB induction in a murine asthma model. Sci Rep. 2017;7(1):9919. Epub 2017/09/01. doi: 10.1038/s41598-017-09349-0 [pii]. 28855674; PubMed Central PMCID: PMC5577320.

5. Hirose K, Iwata A, Tamachi T, Nakajima H. Allergic airway inflammation: key players beyond the Th2 cell pathway. Immunol Rev. 2017;278(1):145–61. Epub 2017/06/29. doi: 10.1111/imr.12540 28658544.

6. Vultaggio A, Matucci A, Nencini F, Pratesi S, Petroni G, Cammelli D, et al. Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab. Int Arch Allergy Immunol. 2012;159(3):321–6. Epub 2012/08/01. doi: 10.1159/000336839 000336839 [pii]. 22846615.

7. Al Efraij K, FitzGerald JM. Current and emerging treatments for severe asthma. J Thorac Dis. 2015;7(11):E522–5. Epub 2015/12/31. doi: 10.3978/j.issn.2072-1439.2015.10.73 jtd-07-11-E522 [pii]. 26716048; PubMed Central PMCID: PMC4669299.

8. Murthy D, Attri KS, Gokhale RS. Network, nodes and nexus: systems approach to multitarget therapeutics. Curr Opin Biotechnol. 2013;24(6):1129–36. Epub 2013/03/05. doi: 10.1016/j.copbio.2013.02.009 S0958-1669(13)00023-2 [pii]. 23453398.

9. Liang TZ, Chao JH. Corticosteroids, Inhaled. 2017. Epub 2017/12/22. NBK470556 [bookaccession]. PubMed PMID: 29261858.

10. Shaltout HA, Westwood BM, Averill DB, Ferrario CM, Figueroa JP, Diz DI, et al. Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. Am J Physiol Renal Physiol. 2007;292(1):8.

11. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100(14):8258–63. doi: 10.1073/pnas.1432869100 12829792

12. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264(3):224–36. doi: 10.1111/j.1365-2796.2008.01981.x 18793332

13. Geara AS, Azzi J, Jurewicz M, Abdi R. The renin-angiotensin system: an old, newly discovered player in immunoregulation. Transplant Rev. 2009;23(3):151–8.

14. Ribeiro-Oliveira A Jr., Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Simoes e Silva AC. The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag. 2008;4(4):787–803. 19065996

15. Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin(1–7). Peptides. 1993;14(4):679–84. doi: 10.1016/0196-9781(93)90097-z 8234010

16. da Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa VV, et al. Anti-inflammatory effects of the activation of the angiotensin-(1–7) receptor, MAS, in experimental models of arthritis. J Immunol. 2010;185(9):5569–76. doi: 10.4049/jimmunol.1000314 20935211

17. Dong B, Zhang YH, Dong QL, Yu QT, Zhu L, Li SY, et al. [Overexpression of angiotensin converting enzyme 2 inhibits inflammatory response of atherosclerotic plaques in hypercholesterolemic rabbits]. Zhonghua Xin Xue Guan Bing Za Zhi. 2009;37(7):622–5. 19961735

18. Khajah MA, Fateel MM, Ananthalakshmi KV, Luqmani YA. Anti-Inflammatory Action of Angiotensin 1–7 in Experimental Colitis. PLoS One. 2016;11(3):2016.

19. El-Hashim AZ, Renno WM, Raghupathy R, Abduo HT, Akhtar S, Benter IF. Angiotensin-(1–7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-kappaB-dependent pathways. British journal of pharmacology. 2012;166(6):1964–76. Epub 2012/02/22. doi: 10.1111/j.1476-5381.2012.01905.x 22339213; PubMed Central PMCID: PMC3402818.

20. Rodrigues-Machado MG, Magalhaes GS, Cardoso JA, Kangussu LM, Murari A, Caliari MV, et al. AVE 0991, a non-peptide mimic of angiotensin-(1–7) effects, attenuates pulmonary remodelling in a model of chronic asthma. British journal of pharmacology. 2013;170(4):835–46. Epub 2013/07/31. doi: 10.1111/bph.12318 23889691; PubMed Central PMCID: PMC3799597.

21. Magalhaes GS, Rodrigues-Machado MG, Motta-Santos D, Alenina N, Bader M, Santos RA, et al. Chronic allergic pulmonary inflammation is aggravated in angiotensin-(1–7) Mas receptor knockout mice. American journal of physiology Lung cellular and molecular physiology. 2016;311(6):L1141–L8. Epub 2016/11/07. doi: 10.1152/ajplung.00029.2016 ajplung.00029.2016 [pii]. 27815255.

22. da Silveira KD, Pompermayer Bosco KS, Diniz LR, Carmona AK, Cassali GD, Bruna-Romero O, et al. ACE2-angiotensin-(1–7)-Mas axis in renal ischaemia/reperfusion injury in rats. Clin Sci. 2010;119(9):385–94. doi: 10.1042/CS20090554 20528771

23. Benter IF, Yousif MH, Dhaunsi GS, Kaur J, Chappell MC, Diz DI. Angiotensin-(1–7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol. 2008;28(1):25–33. doi: 10.1159/000108758 17890855

24. Khajah MA, Fateel MM, Ananthalakshmi KV, Luqmani YA. Anti-inflammatory action of angiotensin 1–7 in experimental colitis may be mediated through modulation of serum cytokines/chemokines and immune cell functions. Dev Comp Immunol. 2017;74:200–8. Epub 2017/05/11. S0145-305X(17)30079-4 [pii] doi: 10.1016/j.dci.2017.05.005 28487234.

25. Amishima M, Munakata M, Nasuhara Y, Sato A, Takahashi T, Homma Y, et al. Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway. American journal of respiratory and critical care medicine. 1998;157(6 Pt 1):1907–12. doi: 10.1164/ajrccm.157.6.9609040 9620926.

26. Puddicombe SM, Polosa R, Richter A, Krishna MT, Howarth PH, Holgate ST, et al. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J. 2000;14(10):1362–74. doi: 10.1096/fj.14.10.1362 10877829.

27. Song L, Tang H, Liu D, Song J, Wu Y, Qu S, et al. The Chronic and Short-Term Effects of Gefinitib on Airway Remodeling and Inflammation in a Mouse Model of Asthma. Cell Physiol Biochem. 2016;38(1):194–206. Epub 2016/01/20. doi: 10.1159/000438621 000438621 [pii]. 26784930.

28. Tan WL, Jain A, Takano A, Newell EW, Iyer NG, Lim WT, et al. Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol. 2016;17(8):e347–62. Epub 2016/08/12. doi: 10.1016/S1470-2045(16)30123-1 S1470-2045(16)30123-1 [pii]. 27511159.

29. Harskamp LR, Gansevoort RT, van Goor H, Meijer E. The epidermal growth factor receptor pathway in chronic kidney diseases. Nat Rev Nephrol. 2016;12(8):496–506. Epub 2016/07/05. doi: 10.1038/nrneph.2016.91 nrneph.2016.91 [pii]. 27374915.

30. Akhtar S, Almubrad T, Bron AJ, Yousif MH, Benter IF, Akhtar S. Role of epidermal growth factor receptor (EGFR) in corneal remodelling in diabetes. Acta ophthalmologica. 2009;87(8):881–9. Epub 2009/05/07. doi: 10.1111/j.1755-3768.2008.01434.x 19416119.

31. Benter IF, Yousif MH, Griffiths SM, Benboubetra M, Akhtar S. Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed. British journal of pharmacology. 2005;145(6):829–36. Epub 2005/04/27. doi: 10.1038/sj.bjp.0706238 15852031; PubMed Central PMCID: PMC1576192.

32. Akhtar S, Yousif MH, Chandrasekhar B, Benter IF. Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury. PloS one. 2012;7(6):e39066. Epub 2012/06/22. doi: 10.1371/journal.pone.0039066 22720029; PubMed Central PMCID: PMC3374768.

33. Vargaftig BB, Singer M. Leukotrienes mediate part of Ova-induced lung effects in mice via EGFR. American journal of physiology Lung cellular and molecular physiology. 2003;285(4):L808–18. doi: 10.1152/ajplung.00377.2002 12794006.

34. Tamaoka M, Hassan M, McGovern T, Ramos-Barbon D, Jo T, Yoshizawa Y, et al. The epidermal growth factor receptor mediates allergic airway remodelling in the rat. Eur Respir J. 2008;32(5):1213–23. doi: 10.1183/09031936.00166907 18653647.

35. Burkhardt AL, Brunswick M, Bolen JB, Mond JJ. Anti-immunoglobulin stimulation of B lymphocytes activates src-related protein-tyrosine kinases. Proceedings of the National Academy of Sciences of the United States of America. 1991;88(16):7410–4. doi: 10.1073/pnas.88.16.7410 1714601; PubMed Central PMCID: PMC52305.

36. Pazdrak K, Justement L, Alam R. Mechanism of inhibition of eosinophil activation by transforming growth factor-beta. Inhibition of Lyn, MAP, Jak2 kinases and STAT1 nuclear factor. J Immunol. 1995;155(9):4454–8. 7594607.

37. Corey S, Eguinoa A, Puyana-Theall K, Bolen JB, Cantley L, Mollinedo F, et al. Granulocyte macrophage-colony stimulating factor stimulates both association and activation of phosphoinositide 3OH-kinase and src-related tyrosine kinase(s) in human myeloid derived cells. EMBO J. 1993;12(7):2681–90. 8392933; PubMed Central PMCID: PMC413516.

38. Linnekin D, DeBerry CS, Mou S. Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. The Journal of biological chemistry. 1997;272(43):27450–5. doi: 10.1074/jbc.272.43.27450 9341198.

39. Berton G, Mocsai A, Lowell CA. Src and Syk kinases: key regulators of phagocytic cell activation. Trends in immunology. 2005;26(4):208–14. doi: 10.1016/j.it.2005.02.002 15797511.

40. Masuda ES, Schmitz J. Syk inhibitors as treatment for allergic rhinitis. Pulmonary pharmacology & therapeutics. 2008;21(3):461–7. doi: 10.1016/j.pupt.2007.06.002 17669674.

41. Eiseman E, Bolen JB. Engagement of the high-affinity IgE receptor activates src protein-related tyrosine kinases. Nature. 1992;355(6355):78–80. doi: 10.1038/355078a0 1370575.

42. Correa MF, Barbosa AJR, Teixeira LB, Duarte DA, Simoes SC, Parreiras ESLT, et al. Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H3 and H4 Receptors with Anti-inflammatory Potential. Front Pharmacol. 2017;8:825. Epub 2017/12/01. doi: 10.3389/fphar.2017.00825 29184503; PubMed Central PMCID: PMC5694482.

43. Akhtar S, Yousif MH, Dhaunsi GS, Chandrasekhar B, Al-Farsi O, Benter IF. Angiotensin-(1–7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. Br J Pharmacol. 2012;165(5):1390–400. Epub 2011/08/03. doi: 10.1111/j.1476-5381.2011.01613.x 21806601; PubMed Central PMCID: PMC3372724.

44. Ezeamuzie CI, El-Hashim AZ, Renno WM, Edafiogho IO. Antiallergic and antiasthmatic effects of a novel enhydrazinone ester (CEE-1): inhibition of activation of both mast cells and eosinophils. The Journal of pharmacology and experimental therapeutics. 2014;350(2):444–54. Epub 2014/06/12. doi: 10.1124/jpet.114.213751 jpet.114.213751 [pii]. 24917545.

45. Queto T, Xavier-Elsas P, Gardel MA, de Luca B, Barradas M, Masid D, et al. Inducible nitric oxide synthase/CD95L-dependent suppression of pulmonary and bone marrow eosinophilia by diethylcarbamazine. American journal of respiratory and critical care medicine. 2010;181(5):429–37. Epub 2009/12/17. doi: 10.1164/rccm.200905-0800OC 200905-0800OC [pii]. 20007928.

46. Khajah MA, Fateel MM, Ananthalakshmi KV, Luqmani YA. Anti-Inflammatory Action of Angiotensin 1–7 in Experimental Colitis. PLoS One. 2016;11(3):e0150861. Epub 2016/03/11. doi: 10.1371/journal.pone.0150861 PONE-D-15-53895 [pii]. 26963721; PubMed Central PMCID: PMC4786309.

47. Hansel TT, De Vries IJ, Iff T, Rihs S, Wandzilak M, Betz S, et al. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods. 1991;145(1–2):105–10. Epub 1991/12/15. doi: 10.1016/0022-1759(91)90315-7 1662676.

48. Gomez-Cambronero J, Horn J, Paul CC, Baumann MA. Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway. J Immunol. 2003;171(12):6846–55. doi: 10.4049/jimmunol.171.12.6846 14662891

49. Tan WSD, Liao W, Zhou S, Mei D, Wong WF. Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases. Curr Opin Pharmacol. 2017;40:9–17. Epub 2017/12/31. S1471-4892(17)30210-2 [pii] doi: 10.1016/j.coph.2017.12.002 29288933.

50. Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med. 2017;9(410). Epub 2017/10/06. eaan5616 [pii] doi: 10.1126/scitranslmed.aan56169/410/eaan5616 [pii]. 28978752.

51. Paulis L, Steckelings UM, Unger T. Key advances in antihypertensive treatment. Nat Rev Cardiol. 2012;9(5):276–85. Epub 2012/03/21. doi: 10.1038/nrcardio.2012.33 nrcardio.2012.33 [pii]. 22430830.

52. Machado-Silva A, Passos-Silva D, Santos RA, Sinisterra RD. Therapeutic uses for Angiotensin-(1–7). Expert Opin Ther Pat. 2016;26(6):669–78. Epub 2016/04/29. doi: 10.1080/13543776.2016.1179283 27121991.

53. Etelvino GM, Peluso AA, Santos RA. New components of the renin-angiotensin system: alamandine and the MAS-related G protein-coupled receptor D. Curr Hypertens Rep. 2014;16(6):433. Epub 2014/04/25. doi: 10.1007/s11906-014-0433-0 24760442.

54. Villela D, Leonhardt J, Patel N, Joseph J, Kirsch S, Hallberg A, et al. Angiotensin type 2 receptor (AT2R) and receptor Mas: a complex liaison. Clin Sci (Lond). 2015;128(4):227–34. Epub 2014/10/21. doi: 10.1042/CS20130515 CS20130515 [pii]. 25328009.

55. Wang X, Ye Y, Gong H, Wu J, Yuan J, Wang S, et al. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1–7)-Mas axes in pressure overload-induced cardiac remodeling in male mice. J Mol Cell Cardiol. 2016;97:180–90. Epub 2016/05/24. doi: 10.1016/j.yjmcc.2016.05.012 S0022-2828(16)30144-4 [pii]. 27210827.

56. Passos-Silva DG, Brandan E, Santos RA. Angiotensins as therapeutic targets beyond heart disease. Trends Pharmacol Sci. 2015;36(5):310–20. Epub 2015/04/08. doi: 10.1016/j.tips.2015.03.001 S0165-6147(15)00041-3 [pii]. 25847571.

57. Teixeira LB, Parreiras ESLT, Bruder-Nascimento T, Duarte DA, Simoes SC, Costa RM, et al. Ang-(1–7) is an endogenous beta-arrestin-biased agonist of the AT1 receptor with protective action in cardiac hypertrophy. Sci Rep. 2017;7(1):017–12074.

58. Radermecker C, Louis R, Bureau F, Marichal T. Role of neutrophils in allergic asthma. Curr Opin Immunol. 2018;54:28–34. Epub 2018/06/09. S0952-7915(17)30193-0 [pii] doi: 10.1016/j.coi.2018.05.006 29883877.

59. El-Hashim AZ, Khajah MA, Renno WM, Babyson RS, Uddin M, Benter IF, et al. Src-dependent EGFR transactivation regulates lung inflammation via downstream signaling involving ERK1/2, PI3Kdelta/Akt and NFkappaB induction in a murine asthma model. Sci Rep. 2017;7(1):017–09349.

60. Le Cras TD, Acciani TH, Mushaben EM, Kramer EL, Pastura PA, Hardie WD, et al. Epithelial EGF receptor signaling mediates airway hyperreactivity and remodeling in a mouse model of chronic asthma. Am J Physiol Lung Cell Mol Physiol. 2011;300(3):17.

61. Song X, Wang Z. Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations. Onco Targets Ther. 2017;10:3119–22. doi: 10.2147/OTT.S134523 28790845

62. Le Cras TD, Acciani TH, Mushaben EM, Kramer EL, Pastura PA, Hardie WD, et al. Epithelial EGF receptor signaling mediates airway hyperreactivity and remodeling in a mouse model of chronic asthma. American journal of physiology Lung cellular and molecular physiology. 2011;300(3):L414–21. Epub 2011/01/13. doi: 10.1152/ajplung.00346.2010 ajplung.00346.2010 [pii]. PubMed Central PMCID: PMC3064289. 21224214

63. Ganesan S, Unger BL, Comstock AT, Angel KA, Mancuso P, Martinez FJ, et al. Aberrantly activated EGFR contributes to enhanced IL-8 expression in COPD airways epithelial cells via regulation of nuclear FoxO3A. Thorax. 2013;68(2):131–41. Epub 2012/10/27. doi: 10.1136/thoraxjnl-2012-201719 thoraxjnl-2012-201719 [pii]. 23099361

64. Woodruff PG, Wolff M, Hohlfeld JM, Krug N, Dransfield MT, Sutherland ER, et al. Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2010;181(5):438–45. Epub 2009/12/17. doi: 10.1164/rccm.200909-1415OC 200909-1415OC [pii]. 20007923

65. Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol. 2016;46(4):291–8. Epub 2016/01/31. doi: 10.1093/jjco/hyv207 hyv207 [pii]. PubMed Central PMCID: PMC4886131. 26826719

66. Kuwano M, Sonoda K, Murakami Y, Watari K, Ono M. Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer. Pharmacology & therapeutics. 2016;161:97–110. Epub 2016/03/24. doi: 10.1016/j.pharmthera.2016.03.002 S0163-7258(16)30010-9 [pii]. 27000770.

67. Akhtar S, Chandrasekhar B, Attur S, Dhaunsi GS, Yousif MH, Benter IF. Transactivation of ErbB Family of Receptor Tyrosine Kinases Is Inhibited by Angiotensin-(1–7) via Its Mas Receptor. PLoS One. 2015;10(11):e0141657. Epub 2015/11/05. doi: 10.1371/journal.pone.0141657 PONE-D-15-18084 [pii]. 26536590; PubMed Central PMCID: PMC4633289.

68. Kopec A, Panaszek B, Fal AM. Intracellular signaling pathways in IgE-dependent mast cell activation. Arch Immunol Ther Exp (Warsz). 2006;54(6):393–401. Epub 2006/11/24. doi: 10.1007/s00005-006-0049-4 17122878.

69. Tundwal K, Alam R. JAK and Src tyrosine kinase signaling in asthma. Front Biosci (Landmark Ed). 2012;17:2107–21. Epub 2012/06/02. 4040 [pii]. doi: 10.2741/4040 22652767.

70. Kono Y, Soeda S, Okada Y, Hara H, Araki K, To M, et al. A surrogate marker of airway hyperresponsiveness in patients with bronchial asthma: Allergol Int. 2014 Sep;63(3):487–8. doi: 10.2332/allergolint.13-LE-0656 Epub 2014 May 25. 24851946

71. El-Hashim AZ, Renno WM, Abduo HT, Jaffal SM, Akhtar S, Benter IF. Effect of inhibition of the ubiquitin-proteasome-system and IkappaB kinase on airway inflammation and hyperresponsiveness in a murine model of asthma. Int J Immunopathol Pharmacol. 2011;24(1):33–42. doi: 10.1177/039463201102400105 21496385

72. Bossi F, Bernardi S, De Nardo D, Bramante A, Candido R, Carretta R, et al. Angiotensin 1–7 significantly reduces diabetes-induced leukocyte recruitment both in vivo and in vitro. Atherosclerosis. 2016;244:121–30. doi: 10.1016/j.atherosclerosis.2015.11.017 26630181

73. Magalhaes GS, Barroso LC, Reis AC, Rodrigues-Machado MG, Gregorio JF, Motta-Santos D, et al. Angiotensin-(1–7) Promotes Resolution of Eosinophilic Inflammation in an Experimental Model of Asthma. Front Immunol. 2018;9:58. Epub 2018/02/13. doi: 10.3389/fimmu.2018.00058 29434591; PubMed Central PMCID: PMC5797293.

74. Lommatzsch M. Airway hyperresponsiveness: new insights into the pathogenesis. Semin Respir Crit Care Med. 2012;33(6):579–87. Epub 2012/10/11. doi: 10.1055/s-0032-1325617 23047309.

75. Delescluse I, Mace H, Adcock JJ. Inhibition of airway hyper-responsiveness by TRPV1 antagonists (SB-705498 and PF-04065463) in the unanaesthetized, ovalbumin-sensitized guinea pig. British journal of pharmacology. 2012;166(6):1822–32. Epub 2012/02/11. doi: 10.1111/j.1476-5381.2012.01891.x 22320181; PubMed Central PMCID: PMC3402807.

76. el-Hashim AZ, Jacques CA, Herd CM, Lee TH, Page CP. The effect of R 15.7/HO, an anti-CD18 antibody, on the late airway response and airway hyperresponsiveness in an allergic rabbit model. British journal of pharmacology. 1997;121(4):671–8. Epub 1997/06/01. doi: 10.1038/sj.bjp.0701176 9208133; PubMed Central PMCID: PMC1564734.


Článek vyšel v časopise

PLOS One


2019 Číslo 11